Condition: Liposarcoma · Advanced Solid Tumor · Sponsor: Ascentage Pharma Group Inc.
Part 1 is a phase Ib standard "3 + 3" design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met.
This description comes directly from the study's public registry record.
Yifan Zhai, MD, PhD · +86-20-28068501 · Yzhai@ascentage.com
Guojuan Chen, MD. · +86-20-28068520 · guojuan.chen@ascentage.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Cancer Hospital of The University of Chinese Academy of Sciences | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| Shanghai East Hospital (East Hospital affiliated to Tongji University) | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04785196